Founded in 2018, Wohong Biotechnology is headquartered in Zhangjiang Pharmaceutical Valley, Shanghai, with research and development centers in Beijing and Suzhou. The company has established three core technology platforms covering antibody drug discovery, cell therapy, and AI drug design, and has applied for more than 30 invention patents. At present, there are 8 ongoing projects in the pipeline, of which 2 anti-tumor antibody drugs have entered clinical phase I. The company has obtained hundreds of millions of yuan in financing from well-known venture capital firms and established strategic partnerships with multiple multinational pharmaceutical companies.

Since 2023, Wohong Biotechnology has entered a period of rapid development: its core product WHB-001 has been recognized as an orphan drug by the FDA, and it has reached a technology authorization cooperation of over 500 million yuan with Roche, and completed a B+round of 300 million yuan financing. The company is building a commercial production base that complies with GMP standards, and it is expected that the first product will apply for NDA by 2025. In the next three years, Wohong Biotechnology plans to promote 3-5 innovative drugs to enter the clinical stage and prepare for listing on the Hong Kong Stock Exchange or Science and Technology Innovation Board, creating a globally competitive biopharmaceutical platform.